A Phase 3 interventional study of Sativex® and Placebo in Pain and Peripheral Neuropathy, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-12.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing nabiximols in Pain — none open to participants now, none under way, none of them phase 3. nabiximols · Pain.
Among the 17 studies testing nabiximols in Pain, this one is the 11th largest by enrollment, is one of 6 that started in 2002, is one of 15 in phase 3, and was the 6th registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →None of the 17 studies testing nabiximols in Pain is open now. The open studies under Pain, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 6 started in 2002.
This study's enrollment of 125 is above the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 246 across the 17 interventional studies. Of the 16 that completed or were terminated, 16 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 17 have an industry lead sponsor. The 3 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
20 studies in Pain by Jazz Pharmaceuticals: none open now, none under way, none of them phase 3. Of 20 finished, 20 (100%) have results posted.
Among the 20 studies in Pain by Jazz Pharmaceuticals, this one is the 15th largest by enrollment, is one of 6 that started in 2002, is one of 18 in phase 3, and was the 10th registered.
Jazz Pharmaceuticals’s Pain studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing nabiximols in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jazz Pharmaceuticals’s 20 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving peripheral neuropathic pain associated with allodynia.
This was a six week, multicentre, double blind, randomised, placebo controlled parallel group study to evaluate the efficacy of Sativex®. Subjects with peripheral neuropathic pain characterised by allodynia, were screened to determine eligibility and entered a seven day baseline period. Subjects then returned to the centre for randomisation and dose introduction, and received either placebo or Sativex in a double blind manner for five weeks, with a follow up visit 7 to 10 days after the end of the treatment period. The primary efficacy measure was the difference in pain severity at the end of treatment, measured using a peripheral neuropathic pain 0 to 10 numerical rating scale.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sativex®
Drug: Placebo
containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Also known as: GW-1000-02
containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Also known as: GW-4001-01
Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)
The neuropathic pain Numerical Rating Scale was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = worst possible pain. A negative value indicates an improvement in pain score from baseline.
Time frame: Day 0 to Day 42
Change From Baseline in Mean Neuropathic Pain Scale Score at the End of Treatment
The Neuropathic Pain Scale (NPS) score consisted of a series of assessments of different aspects of pain (intensity, sharpness, hot, dull, cold, sensitive, itchy, unpleasantness, and surface compared with deep), each scored using 11-point Numerical Rating Scales. The NPS score is 0-100 sum of 10 individual pain scores (0-10 NRS, 0= no pain to 10 = most pain imaginable). A negative change from baseline indicates an improvement in pain.
Time frame: Day 0 to Day 42
Change From Baseline in Mean Sleep Quality at the End of Treatment
The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.
Time frame: Day 7 - Day 42
Change From Baseline in the Mean Pain Disability Index Score at the End of Treatment
The Pain Disability Index consisted of seven self-administered questions relating to the effect of the subject's chronic pain on their personal life (family/home responsibilities, social activity, sexual behaviour, life-support activity, recreation, occupation and self-care). Each assessment was scored on an 11-point Numerical Rating Scale ranging from 0 (which equals 'no disability') to 10 (which equals 'total disability'). The total Pain Disability Index is the unweighted sum of the seven Numerical Rating Scale scores. The maximum (worst) total score was 70.
Time frame: Day 0 - Day 42
Change From Baseline in Mean Dynamic Allodynia Test Score at the End of Treatment
Dynamic allodynia was assessed by stroking the skin over the affected area five times with a standardised brush, designed specifically for sensory testing at 5sec intervals, and recording the pain severity on a 0-10 point scale (0= no pain to 10 = most pain imaginable). All strokes were of the same length, minimum 2 cm. Each dynamic allodynia score was calculated as the average of the five strokes. A negative change from baseline indicates an improvement in score.
Time frame: Day 7 and Day 42
Change From Baseline in Mean Static Allodynia Test Score at the End of Treatment
The static allodynia test involved applying pressure to a non-allodynic area (on the contralateral side to the identified allodynic area), and recording the pressure that caused pain to this area. Seventy five percent of the pressure that caused pain to the non-allodynic area (up to the subject's pain/pressure threshold) was then applied to the allodynic area, and an 11-point Numerical Rating Scale pain score recorded (between 0 (no pain)and 10 (most intense pain imaginable)). A negative value indicates an improvement in pain score from baseline.
Time frame: Day 0 - Day 42
Change From Baseline in Mean Total General Health Questionnaire Score at the End of Treatment
The General Health Questionnaire-12 is designed to measure non-psychotic mental disorders. It consists of 12 questions, scored on a 0 to 3 Likert scale to measure and compare psychological morbidity levels, where 0 represents better psychological health. The total General Health Questionnaire-12 score is the unweighted sum of the 12 scores. Zero indicates the best possible psychological health, 36 indicates the worst possible psychological health.
Time frame: Day 7 and Day 42
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Selective Reminding' at the End of Treatment
The Selective Reminding Test measures verbal learning and delayed recall through a multiple-trial list-learning paradigm. Patients are presented aurally with a list of 12 words for trial 1 and are asked to recall as many as possible. For trials 2-6, there is a selective presentation of only those words not recalled on the previous trial. Trial 7 is similar to the other trials but is assessed after an 11-minute delay. The score for the selective reminding test is the unweighted average of seven individual study results (min=0 and max=84) Higher scores indicate a better cognitive performance.
Time frame: Day 7 and Day 42
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for '10/36 Spatial Recall' at the End of Treatment
The 10/36 Spatial Recall Test assesses visual spatial learning and delayed recall. Patients are asked to view a 6 x 6 checkerboard with ten checkers for 10 seconds. They are then asked to recreate the pattern viewed on a blank checkerboard. The number of correct responses from three immediate trials and one delayed trial (7 minute delay) are recorded. The Total number of correct responses is the unweighted sum from the four trials. The score for the 10/36 spatial recall test was the unweighted average of four individual study results (min=0 and max=40). A higher score indicates better cognitive performance.
Time frame: Day 7 and Day 42
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Symbol Digit Modalities' at the End of Treatment
The Symbol Digit Modalities Test measures complex attention and concentration in a task which also requires speed and accuracy in visual search and scanning. Patients are required to associate symbols with numbers and quickly generate the number when shown the symbol. The summary endpoint is the number of correct responses in 90 seconds. The symbol digit modalities test had a min of 0 and max score of 99. A higher score indicates better cognitive performance.
Time frame: Day 7 and Day 42
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Paced Auditory Serial Addition Task' at the End of Treatment
The Paced Auditory Serial Addition Task assesses sustained attention and concentration. A pre-recorded tape is used to present two series of 60 numbers, one every 3 seconds and one every 2 seconds. Patients are asked to add each number to the one immediately preceding it and give the result. The task summary score is the percentage of correct answers is calculated. The PASAT score range was 0% to 100%. Higher scores indicate a better cognitive
Time frame: Day 7 and Day 42
Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Word List Generation' at the End of Treatment
Word list generation measures verbal associative fluency. Patients are given 60 seconds to give as many words beginning with a particular letter. The Total is the unweighted sum of all admissible words over three different trials. Higher scores indicate a better cognitive performance (min=0, max= not defined).
Time frame: Day 7 and Day 42
Subject Global Impression of Change in the Severity of Peripheral Neuropathic Pain at the End of Treatment
Subjects were asked to give their impression of the overall change in their peripheral neuropathic pain since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. The number of subjects who reported an improvement is presented.
Time frame: Day 42
Change From Pre-dose in Mean Intoxication 100 mm Visual Analogue Scale Score at the End of Treatment
Intoxication scores were measured using a 100 mm Visual Analogue Scale, where 0 equalled 'no intoxication' and 100 equalled 'extreme intoxication'. A negative value indicates an improvement in intoxication score from baseline.
Time frame: Day 0 - Day 42
Subject Global Impression of Change in the Severity of Allodynia in Their Chosen Allodynic Area at the End of Treatment
Subjects were asked to give their impression of the overall change in their allodynia since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. A summary of the number and percentage of subjects
Time frame: Day 0 - 42
Incidence of Adverse Events as a Measure of Subject Safety
The number of subjects who reported an adverse event during the course of the study is presented
Time frame: Day 0 - Day 42
| Milestone | Sativex | Placebo |
|---|---|---|
| Started | 63 | 62 |
| Completed | 50 | 55 |
| Not completed | 13 | 7 |
| Withdrew: Adverse event | 11 | 2 |
| Withdrew: Patient non-compliance | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 5 |
The neuropathic pain Numerical Rating Scale was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = worst possible pain. A negative value indicates an improvement in pain score from baseline.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment) | -1.57 ± 2.11 | -0.59 ± 1.38 |
The Neuropathic Pain Scale (NPS) score consisted of a series of assessments of different aspects of pain (intensity, sharpness, hot, dull, cold, sensitive, itchy, unpleasantness, and surface compared with deep), each scored using 11-point Numerical Rating Scales. The NPS score is 0-100 sum of 10 individual pain scores (0-10 NRS, 0= no pain to 10 = most pain imaginable). A negative change from baseline indicates an improvement in pain.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Baseline in Mean Neuropathic Pain Scale Score at the End of Treatment | -9.7 ± 19.35 | -2.0 ± 12.14 |
The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Baseline in Mean Sleep Quality at the End of Treatment | -0.82 ± 0.76 | -0.38 ± 0.68 |
The Pain Disability Index consisted of seven self-administered questions relating to the effect of the subject's chronic pain on their personal life (family/home responsibilities, social activity, sexual behaviour, life-support activity, recreation, occupation and self-care). Each assessment was scored on an 11-point Numerical Rating Scale ranging from 0 (which equals 'no disability') to 10 (which equals 'total disability'). The total Pain Disability Index is the unweighted sum of the seven Numerical Rating Scale scores. The maximum (worst) total score was 70.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Baseline in the Mean Pain Disability Index Score at the End of Treatment | -5.6 ± 12.08 | 0.3 ± 8.71 |
Dynamic allodynia was assessed by stroking the skin over the affected area five times with a standardised brush, designed specifically for sensory testing at 5sec intervals, and recording the pain severity on a 0-10 point scale (0= no pain to 10 = most pain imaginable). All strokes were of the same length, minimum 2 cm. Each dynamic allodynia score was calculated as the average of the five strokes. A negative change from baseline indicates an improvement in score.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Baseline in Mean Dynamic Allodynia Test Score at the End of Treatment | -1.15 ± 2.23 | -0.38 ± 1.72 |
The static allodynia test involved applying pressure to a non-allodynic area (on the contralateral side to the identified allodynic area), and recording the pressure that caused pain to this area. Seventy five percent of the pressure that caused pain to the non-allodynic area (up to the subject's pain/pressure threshold) was then applied to the allodynic area, and an 11-point Numerical Rating Scale pain score recorded (between 0 (no pain)and 10 (most intense pain imaginable)). A negative value indicates an improvement in pain score from baseline.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Baseline in Mean Static Allodynia Test Score at the End of Treatment | 18.22 ± 50.20 | 2.84 ± 44.43 |
The General Health Questionnaire-12 is designed to measure non-psychotic mental disorders. It consists of 12 questions, scored on a 0 to 3 Likert scale to measure and compare psychological morbidity levels, where 0 represents better psychological health. The total General Health Questionnaire-12 score is the unweighted sum of the 12 scores. Zero indicates the best possible psychological health, 36 indicates the worst possible psychological health.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Baseline in Mean Total General Health Questionnaire Score at the End of Treatment | -3.0 ± 7.93 | -2.6 ± 5.72 |
The Selective Reminding Test measures verbal learning and delayed recall through a multiple-trial list-learning paradigm. Patients are presented aurally with a list of 12 words for trial 1 and are asked to recall as many as possible. For trials 2-6, there is a selective presentation of only those words not recalled on the previous trial. Trial 7 is similar to the other trials but is assessed after an 11-minute delay. The score for the selective reminding test is the unweighted average of seven individual study results (min=0 and max=84) Higher scores indicate a better cognitive performance.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Selective Reminding' at the End of Treatment | 0.53 ± 1.10 | 0.48 ± 1.27 |
The 10/36 Spatial Recall Test assesses visual spatial learning and delayed recall. Patients are asked to view a 6 x 6 checkerboard with ten checkers for 10 seconds. They are then asked to recreate the pattern viewed on a blank checkerboard. The number of correct responses from three immediate trials and one delayed trial (7 minute delay) are recorded. The Total number of correct responses is the unweighted sum from the four trials. The score for the 10/36 spatial recall test was the unweighted average of four individual study results (min=0 and max=40). A higher score indicates better cognitive performance.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for '10/36 Spatial Recall' at the End of Treatment | 0.79 ± 2.01 | 0.15 ± 2.12 |
The Symbol Digit Modalities Test measures complex attention and concentration in a task which also requires speed and accuracy in visual search and scanning. Patients are required to associate symbols with numbers and quickly generate the number when shown the symbol. The summary endpoint is the number of correct responses in 90 seconds. The symbol digit modalities test had a min of 0 and max score of 99. A higher score indicates better cognitive performance.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Symbol Digit Modalities' at the End of Treatment | 1.6 ± 5.83 | 3.9 ± 7.38 |
The Paced Auditory Serial Addition Task assesses sustained attention and concentration. A pre-recorded tape is used to present two series of 60 numbers, one every 3 seconds and one every 2 seconds. Patients are asked to add each number to the one immediately preceding it and give the result. The task summary score is the percentage of correct answers is calculated. The PASAT score range was 0% to 100%. Higher scores indicate a better cognitive
| percentage of correct answers | Sativex | Placebo |
|---|---|---|
| Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Paced Auditory Serial Addition Task' at the End of Treatment | 8.0 ± 14.23 | 6.3 ± 9.25 |
Word list generation measures verbal associative fluency. Patients are given 60 seconds to give as many words beginning with a particular letter. The Total is the unweighted sum of all admissible words over three different trials. Higher scores indicate a better cognitive performance (min=0, max= not defined).
| number of words | Sativex | Placebo |
|---|---|---|
| Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Word List Generation' at the End of Treatment | 3.5 ± 7.67 | 3.5 ± 8.47 |
Subjects were asked to give their impression of the overall change in their peripheral neuropathic pain since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. The number of subjects who reported an improvement is presented.
| participants | Sativex | Placebo |
|---|---|---|
| Very Much Improved | 5 | 0 |
| Much Improved | 11 | 6 |
| Minimally Improved | 16 | 6 |
| No Change | 26 | 46 |
| Minimally Worse | 0 | 2 |
| Much Worse | 4 | 2 |
| Very Much Worse | 0 | 0 |
| Missing | 1 | 0 |
Intoxication scores were measured using a 100 mm Visual Analogue Scale, where 0 equalled 'no intoxication' and 100 equalled 'extreme intoxication'. A negative value indicates an improvement in intoxication score from baseline.
| units on a scale | Sativex | Placebo |
|---|---|---|
| Change From Pre-dose in Mean Intoxication 100 mm Visual Analogue Scale Score at the End of Treatment | 3.2 ± 11.39 | 1.4 ± 10.74 |
Subjects were asked to give their impression of the overall change in their allodynia since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. A summary of the number and percentage of subjects
| participants | Sativex | Placebo |
|---|---|---|
| Very Much Improved | 3 | 0 |
| Much Improved | 12 | 3 |
| Minimally Improved | 14 | 8 |
| No Change | 30 | 47 |
| Minimally Worse | 1 | 2 |
| Much Worse | 2 | 2 |
| Very Much Worse | 0 | 0 |
| Missing | 1 | 0 |
The number of subjects who reported an adverse event during the course of the study is presented
| participants | Sativex | Placebo |
|---|---|---|
| Incidence of Adverse Events as a Measure of Subject Safety | 57 | 48 |
Collected over All adverse events occurring from the time of consent to post study follow up i.e.8 weeks were collected. All deaths and serious adverse events occurring within 28 days of the final dose of study medication were also collected.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sativex | — | 1/63 (1.6%) | 57/63 (90.5%) |
| Placebo | — | 2/62 (3.2%) | 48/62 (77.4%) |
| Event | Sativex | Placebo |
|---|---|---|
| FallGeneral disorders | 0/63 | 1/62 |
| Myelitis NOSNervous system disorders | 0/63 | 1/62 |
| BronchopneumoniaInfections and infestations | 1/63 | 0/62 |
| Transient ischaemic attackNervous system disorders | 1/63 | 0/62 |
| HypoaesthesiaNervous system disorders | 0/63 | 0/62 |
| Event | Sativex | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 18/63 | 9/62 |
| NauseaGastrointestinal disorders | 14/63 | 7/62 |
| FatigueGeneral disorders | 13/63 | 5/62 |
| Dry MouthGastrointestinal disorders | 11/63 | 3/62 |
| Headache NOSNervous system disorders | 6/63 | 9/62 |
| Vomiting Not Otherwise Specified (NOS)Gastrointestinal disorders | 8/63 | 3/62 |
| Feeling drunkGeneral disorders | 6/63 | 0/62 |
| ConstipationGastrointestinal disorders | 2/63 | 4/62 |
| Application Site BurningGeneral disorders | 2/63 | 4/62 |
| Diarrhoea NOSGastrointestinal disorders | 4/63 | 0/62 |
| Age, Categorical(Participants) | Sativex | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 51 | 49 | 100 |
| >=65 years | 12 | 13 | 25 |
| Age, Continuous(years) | Sativex | Placebo | Total |
|---|---|---|---|
| Mean | 52.4 ± 15.8 | 54.3 ± 15.2 | 53.4 ± 15.4 |
| Sex: Female, Male(Participants) | Sativex | Placebo | Total |
|---|---|---|---|
| Female | 35 | 39 | 74 |
| Male | 28 | 23 | 51 |
| Region of Enrollment(participants) | Sativex | Placebo | Total |
|---|---|---|---|
| United Kingdom | 51 | 50 | 101 |
| Belgium | 12 | 12 | 24 |
The record gives a start of May 2002, a primary completion of Mar 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 8 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nabiximols